The expiration of the semaglutide patent in Brazil will not lead to immediate price reductions for Ozempic due to regulatory and logistical challenges.
The patent for semaglutide, the active ingredient in Ozempic, will expire on March 20 in Brazil. However, expectations for reduced prices for the weight-loss pen are tempered by significant regulatory and industrial challenges. These issues stem from the complexities involved in bringing a generic version to market and the ongoing demand for the product, which is currently facing supply constraints.
Additionally, Novo Nordisk, the manufacturer of Ozempic, is taking steps to maintain its market presence in Brazil, which ranks as its eighth largest market globally. The company plans to shift its production from imports to local manufacturing in Minas Gerais. This strategic move aims to reduce costs and streamline distribution while also reacting to the competitive landscape following the patent expiration.
Novo Nordisk is assessing whether to appeal a court ruling that denied an extension of their patent, which they originally sought to compensate for the time delays in obtaining regulatory approval. Although the company has faced setbacks in the Superior Court of Justice and may consider bringing the case to the Supreme Federal Court, experts suggest that the likelihood of success is low. A negative outcome could potentially impact pricing strategies and the availability of the drug in the Brazilian market, ultimately affecting patients seeking accessible weight-loss solutions.
